If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksERGO.L Regulatory News (ERGO)

  • There is currently no data for ERGO

Block Listing Six Monthly Return

2 Jan 2019 07:00

RNS Number : 7694L
Ergomed plc
02 January 2019
 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 2 January 2019

 

Name of applicant:

Ergomed plc

Name of scheme:

Ergomed plc Long Term Incentive Plan

Period of return:

From:

2 July 2018

To:

31 December 2018

Balance of unallotted securities under scheme(s) from previous return:

1,800,000 (original admission)

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

nil

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

55,000

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

1,745,000

Number and class of securities originally admitted and the date of admission

1,800,000 ordinary shares of 1p each - 2 July 2018

Total number of securities in issue at the end of the period

45,016,438 ordinary shares of 1p each

 

Name of contact:

Nick Blech - Deputy CFO

Telephone number of contact:

+44 (0)7768 547372

 

 Enquiries:

Ergomed plc

Tel: +44 (0) 1483 503205

Stephen Stamp (Chief Executive Officer)

Stuart Jackson (Chief Financial Officer)

 

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Broker)

 

Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Matthew Neal / Olivia Manser

 

ergomed@consilium-comms.com

MC-Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRFEWFWAFASEEE
Date   Source Headline
4th Apr 20227:00 amRNSIssue of Consideration Shares
1st Apr 202211:25 amRNSTotal Voting Rights
29th Mar 20227:00 amRNSErgomed Preliminary Results 2021
9th Mar 20227:00 amRNSJohn Dawson CBE Appointed to Ergomed Board as NED
1st Mar 20227:00 amRNSTotal Voting Rights
28th Feb 20227:00 amRNSErgomed Notice of Preliminary Results
11th Feb 20224:06 pmRNSDirector's Dealing
9th Feb 20227:00 amRNSAcquisition of ADAMAS
2nd Feb 20225:47 pmRNSHolding(s) in Company
25th Jan 20227:00 amRNSErgomed 2021 Trading Update
4th Jan 20227:00 amRNSTotal Voting Rights and Block Listing Return
1st Dec 20217:00 amRNSTotal Voting Rights
25th Nov 20217:00 amRNSExercise of Options
23rd Nov 20211:10 pmRNSHoldings in Company
15th Nov 20217:00 amRNSErgomed to Present at Jefferies Conference 2021
1st Nov 20217:00 amRNSTotal Voting Rights
25th Oct 20217:00 amRNSExercise of Share Options and Total Voting Rights
21st Oct 202110:20 amRNSHolding(s) in Company
5th Oct 20217:10 amEQSErgomed (ERGO): US is now the biggest market in the mix
5th Oct 20217:01 amEQSCreo Medical (CREO): Initiation - Providing energy for endoscopic surgery
1st Oct 20217:00 amRNSTotal Voting Rights
28th Sep 20217:00 amRNSErgomed Interim results
1st Sep 20217:00 amRNSTotal Voting Rights
23rd Aug 20217:00 amRNSNotice of Interim Results
19th Aug 202112:06 pmRNSHolding(s) in Company
18th Aug 202112:24 pmRNSHolding(s) in Company
18th Aug 202112:09 pmRNSDirector dealings
12th Aug 20217:01 amEQSErgomed (ERGO): Momentum continues with EBITDA upgrades
2nd Aug 20217:00 amRNSTotal Voting Rights
27th Jul 20217:00 amRNSTrading Update
19th Jul 20217:00 amRNSAppointment of Joint Corporate Broker
1st Jul 20217:00 amRNSBlock listing Interim Review
1st Jul 20217:00 amRNSTotal Voting Rights
17th Jun 20214:28 pmRNSHolding(s) in Company
17th Jun 20217:05 amRNSBoard Change
14th Jun 20218:14 amEQSErgomed (ERGO): FY21e EBITDA 'materially ahead' of consensus
10th Jun 202110:00 amRNSResult of AGM
10th Jun 20217:00 amRNSAGM Statement
2nd Jun 20218:00 amEQSEdison Investment Research Limited: Ergomed (ERGO): What's next after stellar 2020 performance?
1st Jun 20217:00 amRNSTotal Voting Rights
28th May 20217:00 amRNSErgomed to Present at Jefferies Conference
14th May 202111:30 amRNSHolding(s) in Company
14th May 20217:00 amRNSNotice of AGM and Annual Report
10th May 20217:00 amRNSBoard Changes
4th May 20217:00 amRNSTotal Voting Rights
29th Apr 20214:35 pmRNSPrice Monitoring Extension
29th Apr 20217:00 amRNSBoard Changes
26th Apr 20217:00 amRNSErgomed expands operations in Japan
1st Apr 20217:00 amRNSTotal Voting Rights
23rd Mar 20217:00 amRNSAudited Full Year Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.